Condition: Colorectal Cancer Metastatic · Advanced Colorectal Cancer · Sponsor: Suzhou Teligene Ltd.
This is a Phase II trial designed to determine the optimal dose and evaluate the effectiveness of TL938 and trastuzumab in treating patients with HER2+ colorectal cancer that has metastasized or recurred and is inoperable.
This description comes directly from the study's public registry record.
Xiaoyang Xia · 8053009373 · Xiaoyang.xia@teligene.com
Liling Ding · 15295298995 · liling.ding@medolution.com
Always discuss trial participation with your own doctor first.
| Cancer Hospital, Chinese Academy of Medical Sciences | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06589830